Business Description
OncoCyte Corp
NAICS : 541380
SIC : 8734
ISIN : US68235C1071
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.29 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.26 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -6.07 | |||||
Beneish M-Score | -3.15 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -19.2 | |||||
3-Year EBITDA Growth Rate | 31.3 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | -36.5 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 45.11 | |||||
12-1 Month Momentum % | -60.41 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.49 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 1.31 | |||||
Days Sales Outstanding | 388.31 | |||||
Days Payable | 375.85 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.7 | |||||
Shareholder Yield % | -39.04 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 27.48 | |||||
Operating Margin % | -1491.48 | |||||
Net Margin % | -1848.37 | |||||
FCF Margin % | -1552.37 | |||||
ROE % | -79.9 | |||||
ROA % | -32.54 | |||||
ROIC % | -30.83 | |||||
ROC (Joel Greenblatt) % | -164.06 | |||||
ROCE % | -16.48 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 12.39 | |||||
PB Ratio | 0.98 | |||||
EV-to-EBIT | -2.06 | |||||
EV-to-EBITDA | -2.38 | |||||
EV-to-Revenue | 17.29 | |||||
EV-to-Forward-Revenue | 10.19 | |||||
EV-to-FCF | -1.11 | |||||
Earnings Yield (Greenblatt) % | -48.54 | |||||
FCF Yield % | -71.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
OncoCyte Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.394 | ||
EPS (TTM) (€) | -1.373 | ||
Beta | 0 | ||
Volatility % | 34.71 | ||
14-Day RSI | 45.11 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 3.12 | ||
12-1 Month Momentum % | -60.41 | ||
52-Week Range (€) | 2.76 - 7.88 | ||
Shares Outstanding (Mil) | 8.26 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
OncoCyte Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
OncoCyte Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
OncoCyte Corp Frequently Asked Questions
What is OncoCyte Corp(FRA:7OC0)'s stock price today?
When is next earnings date of OncoCyte Corp(FRA:7OC0)?
Does OncoCyte Corp(FRA:7OC0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |